Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5641717 | 0.78 | GAA (0.35) | ALDH1A1TSHRHSD17B10MAPTGAA | |
| SCHEMBL9566865 | 0.76 | ALOX15 (0.42) | ALDH1A1TSHRHSD17B10MAPTGAA | |
| SCHEMBL8644984 | 0.74 | CRHR1 (0.46) | ALDH1A1TSHRHSD17B10MAPTKMT2A | |
| SCHEMBL15281583 | 0.74 | MAPT (0.42) | ALDH1A1TSHRHSD17B10MAPTGAA | |
| SCHEMBL2881758 | 0.74 | ESR1 (0.40) | MAPTGAAKMT2AKDM4ECRHR1 | |
| SCHEMBL31418072 | 0.73 | MCL1 (0.46) | ALDH1A1TSHRHSD17B10MAPTGAA | |
| SCHEMBL30219577 | 0.73 | CRHR1 (0.41) | ALDH1A1TSHRHSD17B10MAPTGAA | |
| SCHEMBL9408684 | 0.73 | GAA (0.32) | MAPTGAAKMT2AMAPK1 | |
| SCHEMBL1932115 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10MAPTGAA | |
| SCHEMBL27449226 | 0.73 | GAA (0.55) | ALDH1A1TSHRHSD17B10MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987317-B2 | Inhibition of glutaminase C | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200206149-A1 | INHIBITION OF GLUTAMINASE C | UNIV CORNELL (US) | 2020-07-02 | — | — | US | disclosed |
| US-20130252983-A1 | ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120220610-A1 | INHIBITIONS OF GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012034123-A1 | ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2010111504-A2 | INHIBITION OF GLUTAMINASE C | CORNELL UNIVERSITY (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252983-A1 | ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C | GLS, GLUL, GLS2 | ALDH1A1 2732/4885TSHR 3870/4885HSD17B10 3036/4885 |
| US-20200206149-A1 | INHIBITION OF GLUTAMINASE C | GLS, GLS2, GLUL | ALDH1A1 865/4885TSHR 3590/4885HSD17B10 769/4885 |
| US-20120220610-A1 | INHIBITIONS OF GLUTAMINASE C | GLS, GLS2, GLUL | ALDH1A1 960/4885TSHR 3566/4885HSD17B10 731/4885 |
| US-10987317-B2 | Inhibition of glutaminase C | GLS, GLS2, GLUL | ALDH1A1 865/4885TSHR 3590/4885HSD17B10 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.